Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients

Rhea-AI Summary

Relief Therapeutics announced the initiation of a phase 2/3 trial for inhaled RLF-100(TM) to treat severe COVID-19 patients, in collaboration with UCI Health. The trial aims to determine if RLF-100(TM) can prevent progression to critical illness. Additionally, top-line data from a previous phase 2b/3 trial of intravenous RLF-100(TM) is expected to be released this month after ongoing statistical analyses. Relief's focus is on developing treatments for respiratory diseases based on clinically tested molecules.

Positive

• Initiation of phase 2/3 trial for inhaled RLF-100(TM) targeting severe COVID-19.
• Expected release of top-line data from phase 2b/3 trial of intravenous RLF-100(TM) this month.

Negative

• None.

• Top-line data from intravenous RLF-100(TM) phase 2b/3 trial expected to be released this month

GENEVA, SWITZERLAND / ACCESSWIRE / February 08, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTCQB:RLFTF) ("Relief" or the "Company") affirms that its collaboration partner NeuroRx, Inc. has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100^TM (aviptadil; ZYESAMI(TM)) for the treatment of patients with severe COVID-19 in partnership with UCI Health of the University of California, Irvine. The objective of the current study is to determine whether RLF-100^TM, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-19-infected individuals. For further information, please refer to: https://www.neurorxpharma.com/press-releases/neurorx-initiates-phase-2-3-study-of-inhaled-zyesami-for-severe-covid-19-with-uci-health/.

Furthermore, top-line data from the previously completed phase 2b/3 trial of the intravenous ("IV") formulation of RLF-100^TM are slated to be released this month. The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed.

###

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100^TM (aviptadil) is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100^TM.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

www.relieftherapeutics.com

Follow us on LinkedIn

CONTACT: RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA Chairman of the Board Mail: contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES: MC Services AG Anne Hennecke / Brittney Sojeva Tel.: +49 (0) 211-529-252-14 Mail: relief@mc-services.eu

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of respiratory illnesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and do not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

SOURCE: Relief Therapeutics Holdings AG

View source version on accesswire.com:
https://www.accesswire.com/628278/Relief-Affirms-Initiation-of-Phase-23-Trial-of-Inhaled-RLF-100TM-Aviptadil-ZYESAMITM-in-Severe-COVID-19-Patients

FAQ

What is the purpose of the phase 2/3 trial for RLF-100(TM)?

The trial aims to investigate if inhaled RLF-100(TM) can prevent severe COVID-19 patients from progressing to critical illness.

When will the top-line data from the previous trial of intravenous RLF-100(TM) be released?

The top-line data is expected to be released this month following ongoing statistical analyses.

What is RLF-100(TM) and its relevance to COVID-19?

RLF-100(TM) is a therapeutic candidate being tested for its effectiveness in treating respiratory complications in COVID-19 patients.

What organizations are involved in the RLF-100(TM) clinical trials?

The trials are conducted in collaboration with NeuroRx, Inc. and UCI Health of the University of California, Irvine.

What types of clinical trials is Relief Therapeutics focusing on?

Relief Therapeutics is concentrating on clinical-stage programs targeting respiratory diseases, specifically related to COVID-19.